Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00210236 | Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer(AXIL95) | terminated | Phase 3 | 625 | Institut BergoniéOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06884254 | Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.(EGC102) | withdrawn | Phase 3 | 0 | EirGenix, Inc.INDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT07213206 | CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer(Cinderella) | not yet recruiting | Phase 3 | 1,500 | Fudan UniversityOTHER | 0 | Oct 8, 2025 | clinicaltrials |
| NCT03598712 | Local Compression Seroma DIminution Objective (CLODIS)(CLODIS) | terminated | Phase 3 | 60 | Centre Francois BaclesseOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy(ASCENT-07) | active not recruiting | Phase 3 | 654 | Gilead SciencesINDUSTRY | 28 | Oct 3, 2025 | clinicaltrials |
| NCT07166042 | Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies(Med-RT BG) | recruiting | Phase 3 | 34 | University of UtahOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03264547 | A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | completed | Phase 3 | 446 | Japan Breast Cancer Research GroupOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07190443 | Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)(AURA) | recruiting | Phase 3 | 290 | Japanese Foundation for Cancer ResearchOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT03367572 | Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer | completed | Phase 3 | 1,363 | University of Rochester NCORP Research BaseOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT00210210 | Administration of Ketamine to Prevent the Post-operative Pain(KETAMINE) | completed | Phase 3 | 230 | Institut BergoniéOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02839473 | Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial(HYDROSORB) | completed | Phase 3 | 278 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04327063 | MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery(MIRs 04) | completed | Phase 3 | 182 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT03778931 | Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(EMERALD) | completed | Phase 3 | 478 | Stemline Therapeutics, Inc.INDUSTRY | 17 | Sep 15, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | recruiting | Phase 3 | 400 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04254263 | Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer(ATP) | recruiting | Phase 3 | 316 | RenJi HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer(AMEERA-5) | terminated | Phase 3 | 1,068 | SanofiINDUSTRY | 30 | Sep 11, 2025 | clinicaltrials |
| NCT02514681 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer(PRECIOUS) | completed | Phase 3 | 226 | Japan Breast Cancer Research GroupOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04379570 | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | active not recruiting | Phase 3 | 1,167 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05063786 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)(ALPHABET) | active not recruiting | Phase 3 | 27 | Spanish Breast Cancer Research GroupOTHER | 6 | Sep 8, 2025 | clinicaltrials |
| NCT04815083 | Fluorescence Imaging of Carcinoma During Breast Conserving Surgery | terminated | Phase 3 | 57 | SBI ALApharma Canada, Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT04134598 | ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer(EUROPA) | active not recruiting | Phase 3 | 926 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | completed | Phase 2 / Phase 3 | 130 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05744687 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | recruiting | Phase 2 / Phase 3 | 374 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07008976 | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 246 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06597175 | Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy(ORIGO) | completed | Phase 3 | 300 | Olive HealthcareINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05802225 | Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer(PREFER) | active not recruiting | Phase 3 | 398 | BiocadINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05257395 | A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer | active not recruiting | Phase 3 | 397 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease(ZEST) | active not recruiting | Phase 3 | 40 | GlaxoSmithKlineINDUSTRY | 27 | Jul 16, 2025 | clinicaltrials |
| NCT04752332 | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer(eMonarcHER) | terminated | Phase 3 | 111 | Eli Lilly and CompanyINDUSTRY | 20 | Jul 15, 2025 | clinicaltrials |
| NCT07066280 | Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer | recruiting | Phase 3 | 326 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | completed | Phase 3 | 3,270 | National Cancer Institute (NCI)NIH | 4 | Jul 14, 2025 | clinicaltrials |
| NCT02455141 | Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer(TCTN) | active not recruiting | Phase 3 | 786 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
| NCT06835400 | Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | not yet recruiting | Phase 3 | 340 | Health Hope PharmaINDUSTRY | 0 | Jul 11, 2025 | clinicaltrials |
| NCT07057427 | Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 812 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06839001 | CRYoablation for Small Tumors As Local Treatment - SIX Trial(CRYSTAL - SIX) | recruiting | Phase 3 | 750 | Hospital do CoracaoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07003074 | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 642 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 20, 2025source: clinicaltrials